Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

Molecular pathways and cellular metabolism in colorectal cancer.

Hagland HR, Berg M, Jolma IW, Carlsen A, Søreide K.

Dig Surg. 2013;30(1):12-25. doi: 10.1159/000347166. Epub 2013 Apr 10. Review.

2.

The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer.

Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D, Compton C, Mayer RJ, Goldberg R, Bertagnolli MM, Boland CR.

Gastroenterology. 2007 Jan;132(1):127-38. Epub 2006 Sep 20.

PMID:
17087942
3.

Clinicopathologic characteristics, CpG island methylator phenotype, and BRAF mutations in microsatellite-stable colorectal cancers without chromosomal instability.

Kakar S, Deng G, Sahai V, Matsuzaki K, Tanaka H, Miura S, Kim YS.

Arch Pathol Lab Med. 2008 Jun;132(6):958-64. doi: 10.1043/1543-2165(2008)132[958:CCCIMP]2.0.CO;2.

PMID:
18517279
4.

Molecular pathways in colorectal cancer.

Al-Sohaily S, Biankin A, Leong R, Kohonen-Corish M, Warusavitarne J.

J Gastroenterol Hepatol. 2012 Sep;27(9):1423-31. doi: 10.1111/j.1440-1746.2012.07200.x. Review.

PMID:
22694276
5.

Evolving molecular classification by genomic and proteomic biomarkers in colorectal cancer: potential implications for the surgical oncologist.

Søreide K, Nedrebø BS, Knapp JC, Glomsaker TB, Søreide JA, Kørner H.

Surg Oncol. 2009 Mar;18(1):31-50. doi: 10.1016/j.suronc.2008.06.006. Epub 2008 Jul 30. Review.

PMID:
18672360
6.

Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype.

Toyota M, Ohe-Toyota M, Ahuja N, Issa JP.

Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):710-5.

7.

Intermediate- and low-methylation epigenotypes do not correspond to CpG island methylator phenotype (low and -zero) in colorectal cancer.

Karpinski P, Walter M, Szmida E, Ramsey D, Misiak B, Kozlowska J, Bebenek M, Grzebieniak Z, Blin N, Laczmanski L, Sasiadek MM.

Cancer Epidemiol Biomarkers Prev. 2013 Feb;22(2):201-8. doi: 10.1158/1055-9965.EPI-12-0157. Epub 2012 Nov 21.

8.

[Colorectal cancer biology].

Perkins G, Laurent-Puig P.

Rev Prat. 2015 Jun;65(6):802-6. French.

PMID:
26298904
9.

Identification of the methylator (serrated) colorectal cancer phenotype through precursor serrated polyps.

Messick CA, Church J, Casey G, Kalady MF.

Dis Colon Rectum. 2009 Sep;52(9):1535-41. doi: 10.1007/DCR.0b013e3181afbe05.

PMID:
19690479
10.

Stage III colorectal cancer: molecular disparity between primary cancers and lymph node metastases.

Messick CA, Church JM, Liu X, Ting AH, Kalady MF.

Ann Surg Oncol. 2010 Feb;17(2):425-31. doi: 10.1245/s10434-009-0783-z. Epub 2009 Nov 3.

PMID:
19885699
11.

Application of molecular techniques in the diagnosis, prognosis and management of patients with colorectal cancer: a practical approach.

Legolvan MP, Taliano RJ, Resnick MB.

Hum Pathol. 2012 Aug;43(8):1157-68. doi: 10.1016/j.humpath.2012.03.003. Epub 2012 Jun 1. Review.

PMID:
22658275
12.

Aurora-A expression is independently associated with chromosomal instability in colorectal cancer.

Baba Y, Nosho K, Shima K, Irahara N, Kure S, Toyoda S, Kirkner GJ, Goel A, Fuchs CS, Ogino S.

Neoplasia. 2009 May;11(5):418-25.

13.

Four molecular subtypes of colorectal cancer and their precursor lesions.

Kang GH.

Arch Pathol Lab Med. 2011 Jun;135(6):698-703. doi: 10.1043/2010-0523-RA.1. Review.

PMID:
21631262
14.

The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer.

Karpinski P, Ramsey D, Grzebieniak Z, Sasiadek MM, Blin N.

Mol Cancer Res. 2008 Apr;6(4):585-91. doi: 10.1158/1541-7786.MCR-07-2158.

15.

Colorectal cancer: epigenetic alterations and their clinical implications.

Puccini A, Berger MD, Naseem M, Tokunaga R, Battaglin F, Cao S, Hanna DL, McSkane M, Soni S, Zhang W, Lenz HJ.

Biochim Biophys Acta. 2017 Dec;1868(2):439-448. doi: 10.1016/j.bbcan.2017.09.003. Epub 2017 Sep 20. Review.

PMID:
28939182
16.

Promoter CpG island methylation markers in colorectal cancer: the road ahead.

Draht MX, Riedl RR, Niessen H, Carvalho B, Meijer GA, Herman JG, van Engeland M, Melotte V, Smits KM.

Epigenomics. 2012 Apr;4(2):179-94. doi: 10.2217/epi.12.9. Review.

PMID:
22449189
18.

Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention.

Colussi D, Brandi G, Bazzoli F, Ricciardiello L.

Int J Mol Sci. 2013 Aug 7;14(8):16365-85. doi: 10.3390/ijms140816365. Review.

19.

[Genetics and molecular classification of colorectal cancer].

Søreide K.

Tidsskr Nor Laegeforen. 2007 Nov 1;127(21):2818-23. Review. Norwegian.

20.

Aberrant methylation of the Cyclooxygenase 2 CpG island in colorectal tumors.

Toyota M, Shen L, Ohe-Toyota M, Hamilton SR, Sinicrope FA, Issa JP.

Cancer Res. 2000 Aug 1;60(15):4044-8.

Supplemental Content

Support Center